These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

523 related articles for article (PubMed ID: 29501599)

  • 1. Associations Among Mucosal and Transmural Healing and Fecal Level of Calprotectin in Children With Crohn's Disease.
    Weinstein-Nakar I; Focht G; Church P; Walters TD; Abitbol G; Anupindi S; Berteloot L; Hulst JM; Ruemmele F; Lemberg DA; Leach ST; Cytter R; Greer ML; Griffiths AM; Turner D;
    Clin Gastroenterol Hepatol; 2018 Jul; 16(7):1089-1097.e4. PubMed ID: 29501599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and Validation of the Mucosal Inflammation Noninvasive Index For Pediatric Crohn's Disease.
    Cozijnsen MA; Ben Shoham A; Kang B; Choe BH; Choe YH; Jongsma MME; Russell RK; Ruemmele FM; Escher JC; de Ridder L; Koletzko S; Martín-de-Carpi J; Hyams J; Walters T; Griffiths A; Turner D
    Clin Gastroenterol Hepatol; 2020 Jan; 18(1):133-140.e1. PubMed ID: 30981008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Level of Fecal Calprotectin Correlates With Severity of Small Bowel Crohn's Disease, Measured by Balloon-assisted Enteroscopy and Computed Tomography Enterography.
    Arai T; Takeuchi K; Miyamura M; Ishikawa R; Yamada A; Katsumata M; Igarashi Y; Suzuki Y
    Clin Gastroenterol Hepatol; 2017 Jan; 15(1):56-62. PubMed ID: 27565523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.
    D'Haens G; Ferrante M; Vermeire S; Baert F; Noman M; Moortgat L; Geens P; Iwens D; Aerden I; Van Assche G; Van Olmen G; Rutgeerts P
    Inflamm Bowel Dis; 2012 Dec; 18(12):2218-24. PubMed ID: 22344983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of disease activity of Crohn's disease through fecal calprotectin evaluated by balloon-assisted endoscopy.
    Iwamoto F; Matsuoka K; Motobayashi M; Takenaka K; Kuno T; Tanaka K; Tsukui Y; Kobayashi S; Yoshida T; Fujii T; Saito E; Yamaguchi T; Nagahori M; Sato T; Ohtsuka K; Enomoto N; Watanabe M
    J Gastroenterol Hepatol; 2018 Dec; 33(12):1984-1989. PubMed ID: 29889986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings.
    Sipponen T; Savilahti E; Kolho KL; Nuutinen H; Turunen U; Färkkilä M
    Inflamm Bowel Dis; 2008 Jan; 14(1):40-6. PubMed ID: 18022866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease.
    Kostas A; Siakavellas SI; Kosmidis C; Takou A; Nikou J; Maropoulos G; Vlachogiannakos J; Papatheodoridis GV; Papaconstantinou I; Bamias G
    World J Gastroenterol; 2017 Nov; 23(41):7387-7396. PubMed ID: 29151692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association Between Level of Fecal Calprotectin and Progression of Crohn's Disease.
    Kennedy NA; Jones GR; Plevris N; Patenden R; Arnott ID; Lees CW
    Clin Gastroenterol Hepatol; 2019 Oct; 17(11):2269-2276.e4. PubMed ID: 30772585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fecal Calprotectin in Ileal Crohn's Disease: Relationship with Magnetic Resonance Enterography and a Pathology Score.
    Cerrillo E; Beltrán B; Pous S; Echarri A; Gallego JC; Iborra M; Pamies J; Nos P
    Inflamm Bowel Dis; 2015 Jul; 21(7):1572-9. PubMed ID: 26052967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI.
    Schoepfer AM; Beglinger C; Straumann A; Trummler M; Vavricka SR; Bruegger LE; Seibold F
    Am J Gastroenterol; 2010 Jan; 105(1):162-9. PubMed ID: 19755969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of disease location on fecal calprotectin levels in Crohn's disease.
    Gecse KB; Brandse JF; van Wilpe S; Löwenberg M; Ponsioen C; van den Brink G; D'Haens G
    Scand J Gastroenterol; 2015 Jul; 50(7):841-7. PubMed ID: 25636819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Faecal Calprotectin Level and Combined Endoscopic and Radiological Healing in Patients With Crohn's Disease Receiving Anti-tumour Necrosis Factor Therapy.
    Noh SM; Oh EH; Park SH; Lee JB; Kim JY; Park JC; Kim J; Ham NS; Hwang SW; Park SH; Yang DH; Byeon JS; Myung SJ; Yang SK; Ye BD
    J Crohns Colitis; 2020 Sep; 14(9):1231-1240. PubMed ID: 32157278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Symptoms Do Not Correlate With Findings From Colonoscopy in Children With Inflammatory Bowel Disease and Primary Sclerosing Cholangitis.
    Ricciuto A; Fish J; Carman N; Walters TD; Church PC; Hansen BE; Crowley E; Siddiqui I; Nguyen GC; Kamath BM; Griffiths AM
    Clin Gastroenterol Hepatol; 2018 Jul; 16(7):1098-1105.e1. PubMed ID: 29378308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease.
    Sipponen T; Savilahti E; Kärkkäinen P; Kolho KL; Nuutinen H; Turunen U; Färkkilä M
    Inflamm Bowel Dis; 2008 Oct; 14(10):1392-8. PubMed ID: 18484671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accurate cut-offs for predicting endoscopic activity and mucosal healing in Crohn's disease with fecal calprotectin.
    Vázquez Morón JM; Pallarés Manrique H; Machancoses FH; Ramos Lora M; Ruiz Frutos C
    Rev Esp Enferm Dig; 2017 Feb; 109(2):130-136. PubMed ID: 28071062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of 18F-FDG PET/MRE Metrics with Inflammatory Biomarkers in Patients with Crohn's Disease: A Pilot Study.
    Domachevsky L; Leibovitzh H; Avni-Biron I; Lichtenstein L; Goldberg N; Nidam M; Groshar D; Bernstine H; Ben-Bassat O
    Contrast Media Mol Imaging; 2017; 2017():7167292. PubMed ID: 29097934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fecal calprotectin and S100A12 have low utility in prediction of small bowel Crohn's disease detected by wireless capsule endoscopy.
    Sipponen T; Haapamäki J; Savilahti E; Alfthan H; Hämäläinen E; Rautiainen H; Koskenpato J; Nuutinen H; Färkkilä M
    Scand J Gastroenterol; 2012 Jul; 47(7):778-84. PubMed ID: 22519419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Consecutive fecal calprotectin measurements for predicting relapse in pediatric Crohn's disease patients.
    Foster AJ; Smyth M; Lakhani A; Jung B; Brant RF; Jacobson K
    World J Gastroenterol; 2019 Mar; 25(10):1266-1277. PubMed ID: 30886509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Noninvasive Fecal Immunochemical Testing and Fecal Calprotectin Predict Mucosal Healing in Inflammatory Bowel Disease: A Prospective Cohort Study.
    Ma C; Lumb R; Walker EV; Foshaug RR; Dang TT; Verma S; Huang VW; Kroeker KI; Wong K; Dieleman LA; Fedorak RN; Halloran BP
    Inflamm Bowel Dis; 2017 Sep; 23(9):1643-1649. PubMed ID: 28644184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tight control using fecal calprotectin and early disease intervention increase the rates of transmural remission in Crohn's disease.
    Fernandes SR; Bernardo S; Saraiva S; Gonçalves AR; Moura Santos P; Valente A; Correia LA; Cortez-Pinto H; Magro F
    United European Gastroenterol J; 2024 May; 12(4):451-458. PubMed ID: 38093503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.